Lloyd H Kasper

This inventor holds 8 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Dartmouth College, Teva Pharmaceutical Industries Limited, Leland Stanford Junior University. Active years: 1997-2017.

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 37.5

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 100(Granted Patents)

Location History:

Norwich, VT (US) (1997 - 2014)
Norwhich, VT (US) (2015 - 2017)

Company Filing History:

Teva Pharmaceutical Industries Limited

patents

2 out of 5,492

Leland Stanford Junior University

patents

where one patent can have more than one assignee

Years Active: 1997-2017

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9625473 - Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate (2017-04-18),

2. 9063153 - Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate (2015-06-23),

3. 8709433 - Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate (2014-04-29),

4. 8586029 - Prevention or treatment of immune-relevant disease by modification of microfloral populations (2013-11-19),

5. 8580278 - Nutraceutical composition and methods for preventing or treating multiple sclerosis (2013-11-12),

6. 6399077 - Method of augmenting T cell-mediated immunity against Toxoplasma gondii (2002-06-04),

7. 5859196 - P30 peptides of Toxoplasma gondii (1999-01-12),

8. 5629414 - Diagnostic genes for toxoplasmosis (1997-05-13),

Title: The Innovations of Lloyd H. Kasper

Introduction

Lloyd H. Kasper is a notable inventor based in Norwich, VT (US), recognized for his contributions to medical science, particularly in the treatment of multiple sclerosis. He holds a total of 8 patents, showcasing his innovative approach to healthcare solutions.

Latest Patents

Among his latest patents is a significant advancement titled "Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate." This patent outlines a method for treating individuals afflicted with multiple sclerosis or a single clinical attack consistent with the condition. The method involves determining whether a patient is a responder to glatiramer acetate by evaluating specific biomarkers in their blood, such as IL-17 concentration, TNF-α concentration, IL-2 concentration, and IFN-γ concentration. The pharmaceutical composition is then administered only if the patient is identified as a responder, enhancing the treatment's effectiveness.

Career Highlights

Lloyd H. Kasper has had a distinguished career, working with esteemed institutions such as Dartmouth College and Teva Pharmaceutical Industries Limited. His work has significantly impacted the field of neurology and the treatment of autoimmune diseases.

Collaborations

Throughout his career, Kasper has collaborated with notable colleagues, including Jacqueline Y. Smith and John Charles Boothroyd. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Lloyd H. Kasper's work exemplifies the intersection of innovation and healthcare, particularly in the treatment of multiple sclerosis. His patents and collaborations reflect a commitment to improving patient outcomes through scientific advancements.